An inactivated cell-culture vaccine against yellow fever

Thomas P. Monath, Elizabeth Fowler, Casey T. Johnson, John Balser, Merribeth J. Morin, Maggie Sisti, Dennis W. Trent

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

BACKGROUND: Yellow fever is a lethal viral hemorrhagic fever occurring in Africa and South America. A highly effective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serious adverse events, including viscerotropic disease, which is associated with a high rate of death. A safer, nonreplicating vaccine is needed. METHODS: In a double-blind, placebo-controlled, dose-escalation, phase 1 study of 60 healthy subjects between 18 and 49 years of age, we investigated the safety and immunogenicity of XRX-001 purified whole-virus, β-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and adsorbed to aluminum hydroxide (alum) adjuvant. On two visits 21 days apart, subjects received intramuscular injections of vaccine that contained 0.48 μg or 4.8 μg of antigen. Levels of neutralizing antibodies were measured at baseline and on days 21, 31, and 42. RESULTS: The vaccine induced the development of neutralizing antibodies in 100% of subjects receiving 4.8 μg of antigen in each injection and in 88% of subjects receiving 0.48 μg of antigen in each injection. Antibody levels increased by day 10 after the second injection, at which time levels were significantly higher with the 4.8-μg formulation than with the 0.48-μg formulation (geometric mean titer, 146 vs. 39; P<0.001). Three adverse events occurred at a higher incidence in the two vaccine groups than in the placebo group: mild pain, tenderness, and (much less frequently) itching at the injection site. One case of urticaria was observed on day 3 after the second dose of 4.8 μg of vaccine. CONCLUSIONS: A two-dose regimen of the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high percentage of subjects. XRX-001 has the potential to be a safer alternative to live attenuated 17D vaccine. (Funded by Xcellerex; ClinicalTrials.gov number, NCT00995865.)

Original languageEnglish (US)
Pages (from-to)1326-1333
Number of pages8
JournalNew England Journal of Medicine
Volume364
Issue number14
DOIs
StatePublished - Apr 7 2011

Fingerprint

Yellow Fever Vaccine
Vaccines
Cell Culture Techniques
Yellow Fever
Neutralizing Antibodies
Aluminum Hydroxide
Antigens
Inactivated Vaccines
Injections
Viral Hemorrhagic Fevers
Propiolactone
Placebos
Attenuated Vaccines
Vero Cells
South America
Intramuscular Injections
Urticaria
Pruritus
Healthy Volunteers
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monath, T. P., Fowler, E., Johnson, C. T., Balser, J., Morin, M. J., Sisti, M., & Trent, D. W. (2011). An inactivated cell-culture vaccine against yellow fever. New England Journal of Medicine, 364(14), 1326-1333. https://doi.org/10.1056/NEJMoa1009303

An inactivated cell-culture vaccine against yellow fever. / Monath, Thomas P.; Fowler, Elizabeth; Johnson, Casey T.; Balser, John; Morin, Merribeth J.; Sisti, Maggie; Trent, Dennis W.

In: New England Journal of Medicine, Vol. 364, No. 14, 07.04.2011, p. 1326-1333.

Research output: Contribution to journalArticle

Monath, TP, Fowler, E, Johnson, CT, Balser, J, Morin, MJ, Sisti, M & Trent, DW 2011, 'An inactivated cell-culture vaccine against yellow fever', New England Journal of Medicine, vol. 364, no. 14, pp. 1326-1333. https://doi.org/10.1056/NEJMoa1009303
Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M et al. An inactivated cell-culture vaccine against yellow fever. New England Journal of Medicine. 2011 Apr 7;364(14):1326-1333. https://doi.org/10.1056/NEJMoa1009303
Monath, Thomas P. ; Fowler, Elizabeth ; Johnson, Casey T. ; Balser, John ; Morin, Merribeth J. ; Sisti, Maggie ; Trent, Dennis W. / An inactivated cell-culture vaccine against yellow fever. In: New England Journal of Medicine. 2011 ; Vol. 364, No. 14. pp. 1326-1333.
@article{ec3e914942b743cfac8474ef6aa04416,
title = "An inactivated cell-culture vaccine against yellow fever",
abstract = "BACKGROUND: Yellow fever is a lethal viral hemorrhagic fever occurring in Africa and South America. A highly effective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serious adverse events, including viscerotropic disease, which is associated with a high rate of death. A safer, nonreplicating vaccine is needed. METHODS: In a double-blind, placebo-controlled, dose-escalation, phase 1 study of 60 healthy subjects between 18 and 49 years of age, we investigated the safety and immunogenicity of XRX-001 purified whole-virus, β-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and adsorbed to aluminum hydroxide (alum) adjuvant. On two visits 21 days apart, subjects received intramuscular injections of vaccine that contained 0.48 μg or 4.8 μg of antigen. Levels of neutralizing antibodies were measured at baseline and on days 21, 31, and 42. RESULTS: The vaccine induced the development of neutralizing antibodies in 100{\%} of subjects receiving 4.8 μg of antigen in each injection and in 88{\%} of subjects receiving 0.48 μg of antigen in each injection. Antibody levels increased by day 10 after the second injection, at which time levels were significantly higher with the 4.8-μg formulation than with the 0.48-μg formulation (geometric mean titer, 146 vs. 39; P<0.001). Three adverse events occurred at a higher incidence in the two vaccine groups than in the placebo group: mild pain, tenderness, and (much less frequently) itching at the injection site. One case of urticaria was observed on day 3 after the second dose of 4.8 μg of vaccine. CONCLUSIONS: A two-dose regimen of the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high percentage of subjects. XRX-001 has the potential to be a safer alternative to live attenuated 17D vaccine. (Funded by Xcellerex; ClinicalTrials.gov number, NCT00995865.)",
author = "Monath, {Thomas P.} and Elizabeth Fowler and Johnson, {Casey T.} and John Balser and Morin, {Merribeth J.} and Maggie Sisti and Trent, {Dennis W.}",
year = "2011",
month = "4",
day = "7",
doi = "10.1056/NEJMoa1009303",
language = "English (US)",
volume = "364",
pages = "1326--1333",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "14",

}

TY - JOUR

T1 - An inactivated cell-culture vaccine against yellow fever

AU - Monath, Thomas P.

AU - Fowler, Elizabeth

AU - Johnson, Casey T.

AU - Balser, John

AU - Morin, Merribeth J.

AU - Sisti, Maggie

AU - Trent, Dennis W.

PY - 2011/4/7

Y1 - 2011/4/7

N2 - BACKGROUND: Yellow fever is a lethal viral hemorrhagic fever occurring in Africa and South America. A highly effective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serious adverse events, including viscerotropic disease, which is associated with a high rate of death. A safer, nonreplicating vaccine is needed. METHODS: In a double-blind, placebo-controlled, dose-escalation, phase 1 study of 60 healthy subjects between 18 and 49 years of age, we investigated the safety and immunogenicity of XRX-001 purified whole-virus, β-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and adsorbed to aluminum hydroxide (alum) adjuvant. On two visits 21 days apart, subjects received intramuscular injections of vaccine that contained 0.48 μg or 4.8 μg of antigen. Levels of neutralizing antibodies were measured at baseline and on days 21, 31, and 42. RESULTS: The vaccine induced the development of neutralizing antibodies in 100% of subjects receiving 4.8 μg of antigen in each injection and in 88% of subjects receiving 0.48 μg of antigen in each injection. Antibody levels increased by day 10 after the second injection, at which time levels were significantly higher with the 4.8-μg formulation than with the 0.48-μg formulation (geometric mean titer, 146 vs. 39; P<0.001). Three adverse events occurred at a higher incidence in the two vaccine groups than in the placebo group: mild pain, tenderness, and (much less frequently) itching at the injection site. One case of urticaria was observed on day 3 after the second dose of 4.8 μg of vaccine. CONCLUSIONS: A two-dose regimen of the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high percentage of subjects. XRX-001 has the potential to be a safer alternative to live attenuated 17D vaccine. (Funded by Xcellerex; ClinicalTrials.gov number, NCT00995865.)

AB - BACKGROUND: Yellow fever is a lethal viral hemorrhagic fever occurring in Africa and South America. A highly effective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serious adverse events, including viscerotropic disease, which is associated with a high rate of death. A safer, nonreplicating vaccine is needed. METHODS: In a double-blind, placebo-controlled, dose-escalation, phase 1 study of 60 healthy subjects between 18 and 49 years of age, we investigated the safety and immunogenicity of XRX-001 purified whole-virus, β-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and adsorbed to aluminum hydroxide (alum) adjuvant. On two visits 21 days apart, subjects received intramuscular injections of vaccine that contained 0.48 μg or 4.8 μg of antigen. Levels of neutralizing antibodies were measured at baseline and on days 21, 31, and 42. RESULTS: The vaccine induced the development of neutralizing antibodies in 100% of subjects receiving 4.8 μg of antigen in each injection and in 88% of subjects receiving 0.48 μg of antigen in each injection. Antibody levels increased by day 10 after the second injection, at which time levels were significantly higher with the 4.8-μg formulation than with the 0.48-μg formulation (geometric mean titer, 146 vs. 39; P<0.001). Three adverse events occurred at a higher incidence in the two vaccine groups than in the placebo group: mild pain, tenderness, and (much less frequently) itching at the injection site. One case of urticaria was observed on day 3 after the second dose of 4.8 μg of vaccine. CONCLUSIONS: A two-dose regimen of the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high percentage of subjects. XRX-001 has the potential to be a safer alternative to live attenuated 17D vaccine. (Funded by Xcellerex; ClinicalTrials.gov number, NCT00995865.)

UR - http://www.scopus.com/inward/record.url?scp=79953785263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953785263&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1009303

DO - 10.1056/NEJMoa1009303

M3 - Article

VL - 364

SP - 1326

EP - 1333

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 14

ER -